Carotid Paragangliomas Related to Form Involving Multiple Systems (Syndromes and Diseases): A Systematic Literature Review

Francisco S Lozano-Sánchez MD, PhD,1,2,3, Angel Muñoz MD, PhD,1,4, José A de las Heras MD, PhD,5,6, Rogelio González-Sarmiento, MD, PhD,3,7 and M Begoña García-Cenador MD, PhD1,3

1Department of Surgery, School of Medicine, University of Salamanca, Spain
2Service of Angiology and Vascular Surgery, University Hospital, Spain
3Salamanca Institute of Biomedical Research (IBSAL), Spain
4Service of Otorhinolaryngology, School of Medicine, University of Salamanca, Spain
5Department of Biomedical and Diagnostic Sciences, School of Medicine, University of Salamanca, Spain
6Service of Radiology, School of Medicine, University of Salamanca, Spain
7Department of Medicine, School of Medicine, University of Salamanca, Spain

*Corresponding author: M Begoña García-Cenador, MD, PhD, Department of Surgery, School of Medicine, University of Salamanca, 37007 Salamanca, Spain; Salamanca Institute of Biomedical Research (IBSAL), 37007 Salamanca, Spain

Abstract
Carotid paragangliomas are infrequent tumours, generally single, non-functional and benign. Nevertheless, the biology of these tumours occasionally means they are bilateral, multicentric, functional and malignant. Such infrequency and the different ways they manifest themselves pose a diagnostic/therapeutic challenge that is reflected in the final outcomes.

According to the Shamblin classification, 75% of carotid paragangliomas are either Type I (tumour smaller than 4 cm, weakly attached to the carotid arteries, and can be surgically excised in a straightforward manner) or Type II (tumour larger than 4 cm, partially surrounding the carotid arteries, and attached to the vascular adventitia), and 25% of cases are Type III, completely surrounding the carotid bifurcation, firmly attached, so vessel replacement may be considered.

Fewer than 5% of carotid paragangliomas are associated with syndromes (e.g., von Hippel-Lindau disease and Carney triad) or diseases (e.g., thyroid cancer and thymoma), which further complicate their treatment. Morbidity and mortality rates in these cases are clearly different.

This review sets out to address carotid paragangliomas related to syndromes and diseases, with their references being very widely distributed in the literature, with the aim being to highlight their idiosyncrasies of clinical, diagnostic and therapeutic interest. This has involved a systematic literature review of the Medline and Cochrane Library databases up to 1 November 2019, locating 26 articles involving a total of 37 patients.

Conclusions: 1) Patients with these exceptional combinations present major clinical complexity; 2) They pose a medical challenge, with the diagnostic strategy being vitally important (search for associated synchronous and metachronous tumours) together with the therapeutic process (surgical times and priorities); and 3) There must be interdisciplinary cooperation across the different medical specialisms involved.

Keywords
Carotid body tumour, Carotid paraganglioma, Carotid paraganglioma complex, Hereditary tumour syndrome, Inherited syndromes

Abbreviations
PG: Paraganglioma; PHEO: Pheochromocytoma; CPG: Carotid Paraganglioma; JPG: Jugular Paraganglioma; HLD: vonHippel-Lindau Disease; MEN-2: Multiple Endocrine Neoplasia-type 2; NF-1: Neurofibromatosis-type 1; CSS: Carney-Stratakis Syndrome; GIST: Gastrointestinal Stroma Tumour; PCH: Pulmonary Chondroma; HPT: Hyperplasia Parathyroid

Citation: Lozano-Sánchez FS, Muñoz A, las Heras JA, González-Sarmiento R, García-Cenador MB (2020) Carotid Paragangliomas Related to Form Involving Multiple Systems (Syndromes and Diseases): A Systematic Literature Review. Int J Rare Disord 3:024. doi.org/10.23937/2643-4571.1710024
Accepted: November 10, 2020; Published: November 12, 2020
Copyright: © 2020 Lozano-Sánchez FS, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Introduction

Although pheochromocytomas (PHEOs) and paragangliomas (PGs) share a common origin (neural crest-derived chromaffin cells), they are clearly different in terms of location (PHEOs - intra-adrenal paragangliomas (PGs) versus extra-adrenal ones) and biological behaviour. The term paragangliomas is used for tumours that arise from the sympathetic ganglia in the thorax, abdomen and pelvis, as well as the parasympathetic paraganglia in the head and neck. PGs account for 0.012% of all the tumours in the body, and for 0.6% of those located in the head and neck (80% affect the carotid body, 15% involve the glomus-jugular bulb and tympanic nerve, and the remaining 5% affect the vagus nerve) [1,2].

The rate of carotid paragangliomas (CPGs) is estimated to be between 1/30,000 and 1/100,000 people [3,4], affecting more women (ratio of 2:1) in their fifties (age range 18-94). The tumours are usually single ones measuring < 4 cm in diameter, delimited (not attached to the carotids), with slow growth, non-secretary, and benign [5-7].

According to the Shamblin classification [8], 75% of CPGs are either Type I (tumour smaller than 4 cm, weakly attached to the carotid arteries, and can be surgically excised in a straight forward manner) or Type II (tumour larger than 4 cm, partially surrounding the carotid arteries and attached to the vascular adventitia), and Type III with a frequency of 25% of cases, which completely surround the carotid bifurcation and are firmly attached, so vessel replacement may be considered.

Nevertheless, these tumours’ unpredictable biological behaviour and natural history lead to atypical forms (e.g., bilateral, multi-centric, functional, and malignant). Within these, there is a sub-group of CPGs related to different syndromes (von Hippel-Lindau disease, Carney triad, etc) and diseases (thyroid cancer, thymoma, etc), [9-12]. In most cases, these manifestations involve different systems, and present two major characteristics: a) A low rate, which means medical-surgical teams have little experience of them, and b) Diagnostic and therapeutic interest.

This review seeks to adopt a unitary approach to these rare situations that are widely distributed throughout the literature on CPGs, with the aim being to understand and highlight their idiosyncrasies of clinical, diagnostic and therapeutic interest.

Systematic Literature Review

This review involved methodological aspects of the PRISMA statement [13] for a systematic approach.

Search methods: Two researchers (FSL and BGC) and a librarian (MMB) conducted a search in Medline (through PubMed) and the Cochrane Library (through Wiley) from their first records through to the end of the search (1 November 2019). No language restrictions have been applied, nor in terms of type of publication or date of the same. The search was conducted in English.

Inclusion criteria: The following keywords (MESH terms) were used: “Carotid Body Tumour”, “Carotid Paraganglioma”, “von Hippel-Lindau disease”, “Multiple Endocrine Neoplasia-type 2”, “Neurofibromatosis-type 1”, “Carney triad”, “Hereditary tumor syndrome”, “Inherited syndromes”, “Parathyroid adenoma”, “Astrocytoma”, “Thyroid carcinoma”, “Papillary thyroid carcinoma”, “Pituitary tumours”, “Acromegaly”, and “Thymoma”.

Exclusion criteria: a) Sporadic form to PGs, as these are the most frequent cases; b) Familiar form to PGs, relatively frequent cases, and related to PGL syndromes (PGL1 to PGL4). Our experience of the sporadic and familiar forms of CPG has recently been reported [14]; c) CPGs detected in infancy or during pregnancy, as there are recent reviews on the matter [15-19]; and d) CPGs associated with another extracranial ipsilateral carotid pathology (stenosis or aneurisms), as a recent review has been conducted by our group [20].

Data collection and analysis: A search has been made for CPGs related to form involving multiple systems - syndromes and diseases, which are to be found throughout the corresponding literature, with the aim being to highlight and understand their clinical, diagnostic and therapeutic interest.

The search found 457 potential publications, of which 229 were duplications. A reading of the titles and abstracts of the remaining 228 publications, examined separately by two researchers (FSL and BGC), led to 194 references being discarded. This meant that only 34 articles were considered relevant for our review. Following a reading of the full manuscripts, a further eight articles were discarded because they dealt with aspects that were collateral to the search’s core purpose. Finally, this review considered 26 publications (Figure 1). This low number, which is in turn spread across different syndromes and pathologies, does not permit the application of criteria of meta-analysis.

Results

The 26 articles selected [21-46] involve a total of 37 patients with a CPG associated with different syndromes and diseases (Table 1).

The articles included are basically reports on individual cases (12 in Europe, 10 in the US, and one in China), and short series (one in the US, and two in Mexico). Except for two written in German and Spanish, all the others are in English. The article in German was translated in full into English.

This review is divided into two main groups: a) CPGs related to syndromes (n = 17): Five to HLD, one to MEN-
Figure 1: Literature review flowchart.

Lozano-Sánchez et al. Int J Rare Disord 2020, 3:024

2, one to NF-1, nine to the Carney triad, and one to the CSS; and b) CPGs related to other diseases/no syndromes (n = 20): Two to parathyroid adenomas, one to astrocytomas, nine to thyroid cancer, six to pituitary tumours, and two to thymomas.

Table 2 describes the characteristics by groups as follows:

- Gender: Nine males/15 females. This aspect was not reported in any of the other cases (13 patients).
- Patients’ average age at the time of the report: 41.9, with the younger ones in the syndromes group (29.5 vs. 46.1) (p = 0.012). No differences between genders.
- Characteristics of the CPGs: 10 bilateral cases (27%), a malignant one (2.7%) and one catecholamine secreter (2.7%).
- Synchronous or metachronous PG/PHEO (not including bilateral CPGs): 11 patients (29.7%); eight PHEOs (three of them bilateral) and 14 PGs with a different location in six patients (one patient with seven PGs and a bilateral PHEO). Greater frequency in syndromes (35.3% vs. 25%).
- Other tumours unrelated to the disease itself: Nine patients (45%), all in the group unrelated to syndromes; there were mostly adenomas, with different locations.
- Genetic study: 10 positive cases out of the 12 reported.
- Resection of the CPG: This was performed in 19 of the 22 cases reported (the three unoperated cases were as follows: One rejection of surgery, one surgery under way, and one patient deceased before surgery). The surgery performed on tumours associated with the CPG was usually sequential before or after the CPG (there are numerous cases of 3-4 sequential surgical procedures). There are only two reported cases of simultaneous surgery (CPG and thyroids).
| Clinical situation                        | Authors, year [reference] | #  | Age/sex | Side-CPG features                                      | Other tumours (side)                  | Genetic test | Surgery (+) |
|------------------------------------------|---------------------------|----|---------|-------------------------------------------------------|--------------------------------------|--------------|-------------|
| CPG & Syndromes                          |                           |    |         |                                                       |                                      |              |             |
| vonHippel-Lindau disease                 | Hull, et al. 1982 [32]    | 1  | 18/M    | Right CPG malignant (metastasis)                      | PHEO (R)                             | NR           | CPG, PHEO   |
|                                          | Zanelli & van der Walt, 1996 [45] |    | 28/M    | Left CPG                                             | None                                 | NR           | CPG         |
|                                          | Gros, et al. 1996 [30]     | 1  | NR      | CPG                                                  | PHEO                                 | NR           | PHEO        |
|                                          | Schimke, et al. 1998 [41]  | 1  | NR      | Right CPG functional                                 | PHEOs, retinal angiomas, renal and pancreatic cysts | Positive     | CPG, PHEOs  |
|                                          | Majchrzak, et al. 2011 [35]| 1  | 49/F    | Right CPG                                            | Hemangioblastoma intramedullary      | Positive     | Hemang; “I refuse CPG” |
|                                          | Hull, et al. 1982 [32]    | 1  | 18/M    | Right CPG malignant (metastasis)                      | PHEO (R)                             | NR           | CPG, PHEO   |
|                                          | Zanelli & van der Walt, 1996 [45] |    | 28/M    | Left CPG                                             | None                                 | NR           | CPG         |
|                                          | Gros, et al. 1996 [30]     | 1  | NR      | CPG                                                  | PHEO                                 | NR           | PHEO        |
|                                          | Schimke, et al. 1998 [41]  | 1  | NR      | Right CPG functional                                 | PHEOs, retinal angiomas, renal and pancreatic cysts | Positive     | CPG, PHEOs  |
|                                          | Majchrzak, et al. 2011 [35]| 1  | 49/F    | Right CPG                                            | Hemangioblastoma intramedullary      | Positive     | Hemang; “I refuse CPG” |
|                                          | Erickson, et al. 2001 [29] | 1  | NR      | Neck PG (possible CPG)                                | NR                                   | NR           | NR          |
|                                          | Petr & Else, 2018 [39]     | 1  | NR      | Neck PG (possible CPG)                                | Functional PG (thoracic sympathetic chain) | NR           | NR          |
|                                          | Comey, et al. 1999 [27]    | 7  | 25/F    | Neck PG (possible CPG)                                | NR                                   | NR           | NR          |
|                                          | Wintemank, et al. 2001 [43]| 1  | 18/F    | Neck PG (possible CPG)                                | NR                                   | NR           | NR          |
|                                          | Nicholas, et al. 2015 [36] | 1  | 39/M    | Left CPG                                             | GIST, PHEO (L)                       | Positive     | GIST, PHEO, CPG |
|                                          |                           |    |         | One case bilateral/Six unilateral CPG                |                                      |              |             |
|                                          |                           |    |         | Left CPG                                             |                                      |              |             |
|                                          |                           |    |         | Bilateral CPGs (R, large; L, small)                  |                                      |              |             |
| Ref     | Year | Age | Sex | Tumour Type                                      |
|---------|------|-----|-----|-------------------------------------------------|
| Ali, et al. 1994 | 23 | 55 | F | Parathyroid adenoma, pancreatic pseudocysts      |
| Albores & Espino, 1968 | 22 | NR | NR | Parathyroid adenoma, pancreatic pseudocysts      |
| Ophir, 1991 | 37 | NR | NR | Parathyroid adenoma, pancreatic pseudocysts      |
| Steely, et al. 1987 | 42 | 52 | F | Parathyroid adenoma, pancreatic pseudocysts      |

| Ref     | Year | Age | Sex | Tumour Type                                      |
|---------|------|-----|-----|-------------------------------------------------|
| Berg et al. 1976 | 23 | 43 | M | Parathyroid adenoma, pancreatic pseudocysts      |
| Li et al. 2019 | 34 | 43 | F | Parathyroid adenoma, pancreatic pseudocysts      |
| Papathomas, et al. 2013 | 35 | 46 | F | Parathyroid adenoma, pancreatic pseudocysts      |
| Papathomas, et al. 2013 | 35 | 46 | F | Parathyroid adenoma, pancreatic pseudocysts      |

| Ref     | Year | Age | Sex | Tumour Type                                      |
|---------|------|-----|-----|-------------------------------------------------|
| Xekouki, et al. 2012 | 44 | 41 | M | Parathyroid adenoma, pancreatic pseudocysts      |
| Xekouki, et al. 2012 | 44 | 41 | F | Parathyroid adenoma, pancreatic pseudocysts      |

| Ref     | Year | Age | Sex | Tumour Type                                      |
|---------|------|-----|-----|-------------------------------------------------|
| Refior & Mees, 2000 | 40 | 42 | F | Parathyroid adenoma, pancreatic pseudocysts      |
| Bano, et al. 2015 | 24 | 59 | M | Parathyroid adenoma, pancreatic pseudocysts      |

M. Male; F: Female; R: Right; L: Left; NR: Not Reported; PG: Paraganglioma (PGs, multiple); CPG: Carotid Paraganglioma; JPG: Jugular paraganglioma; PHEO: Pheochromocytoma (PHEOs, bilateral); MEN: Multiple Endocrine Neoplasia; GISTs, multipule; PCGs: Pulmonary Chondromas; HPT: Hyperplasia parathyroid. (+) Simultaneous Surgery, **Cowden syndrome; ***Dandy-Walker malformation.
requiring vascular repair) (i.e., Shamblin’s Type III), se
cretory (functional), multiple (including bilateral CPGs),
malign, residual/recurrent, treated by radiotherapy,
with adverse effects with embolization, etc. Morbidity
and mortality rates are clearly different in complex
CPGs compared to simple ones. This latter group in
cludes CPGs associated with syndromes (e.g., HLD), and
other pathologies (e.g. thyroid cancer), which inform
this review.

While the different forms of manifestation of com
plex CPGs account for 1/4 of all CPGs, those associated
with syndromes and diseases are so rare that they in
volve only a handful of individual cases or, exceptional
ly, short series; an estimate of their frequency could be
around 0.8% of overall CPGs (the 37 cases in this review
out of the 5,000 CPGs reported in the literature) or the
3% of complex CPGs (37 out of 1,250 complex CPGs).

The embryological origin of PGs is the neural crest,
involving tumours in the diffuse neuroendocrine system
(formerly APUD). For this reason, and although many
are exceptional cases, and somewhat fewer among fa
miliar forms, CPGs have been described associated
with diverse clinical situations. The latest way of classifying

Mortality: Recorded in only two cases. All other cas
es being monitored/not reported.

Table 3 shows the high number of patients with
tumours unrelated to these syndromes/diseases; in
cluding bilateral CPGs and other PGs/PHEOs and other
tumours (e.g., adenomas, leiomyomas, etc). There is a
difference between the two groups (p < 0.001).

Discussion

PGs in general and CPGs in particular are infrequent
tumours; in fact, the number of CPGs reported in Med
line/PubMed does not exceed 5,000 patients [5,47].
However, despite their low rate, the PGs that affect the
carotid body are the most common among those in the
head and neck.

The majority of CPGs are single tumours, Types I or II
of the Shamblin classification (and therefore resectable
without affecting the carotid axis), non-secretory and
benign; with expert treatment, this normal presenta
tion leads to excellent results. According to Al-Mefty
and Teixeira [48], the remaining CPGs are complex, with
one or more of the following characteristics: Very large,
attached to the carotid arteries (non-resectable or re-

|     | CPG & Syndromes | CPG & Diseases | Total |
|-----|----------------|---------------|-------|
| Cases, n | 17 | 20 | 37 |
| Gender, male/female | 3/3 (11 NR) | 6/12 (2 NR) | 9/15 (13 NR) |
| Age, mean \(\dagger\) | 29.5 + 5.0 (11 NR) | 46.1 + 3.6 (2 NR) | 41.9 + 3.9 (13 NR) |
| Age, mean (male/female) | 28.3/30.7 | 45.8/46.1 | 40.2/43.1 |
| CPG bilateral, n (%) | 2 (11.8%) | 8 (40.0%) | 10 (27.0%) |
| CPG malignant, n (%) | 1 (5.9%) | 0 | 1 (2.7%) |
| CPG functional, n (%) | 1 (5.9%) | 0 | 1 (2.7%) |
| Other PGs/PHEO, n (%) | 6 (35.3%) | 5 (25.0%) | 11 (29.7%) |
| Other tumours, n (%)\* | 0 | 8 (40.0%) | 8 (21.6%) |
| Genetic studies (positive) | 3/3 (14 NR) | 7/9 (11 NR) | 10/12 (25 NR) |
| CPG surgery, n/total | 6/7 (10 NR) | 13/15 (5 NR) | 19/22 (15 NR) |
| Mortality reported | NR | 2 cases | 2 cases |

CPG: Carotid Paraganglioma; PHEO: Pheochromocytoma; NR: Not reported.
\(\dagger\)Age in CPG & Syndromes vs. CPG & Diseases: \(p = 0.012\) (Student’s t-test).
\*Unrelated to these syndromes or diseases.

Table 3: Multi-tumour and carotid paragangliomas (CPG) related to syndromes and diseases. Literature review.

N patients | CPG & Syndromes - Genetic + / - / NR | CPG & Diseases - Genetic + / - / NR | Total
--- | --- | --- | ---
With multi-tumours | 4 (23.5%)\*1/0/3 | 15 (75%)\*9/0/6 | 19 (51.4%) 10/0/9
Without multi-tumours | 6 (35.3%), 2/0/4 | 5 (25%) 1/2/2 | 11 (29.7%) 3/2/6
Not reported | 7 (41.2%) 0/0/7 | 0 | 7 (18.9%) 0/0/7
Total cases | 17 | 20 | 37

\* Included bilateral CPG, other PGs and other tumour unrelated to these syndromes.
\* Included bilateral CPG, other PGs/PHEOs and other tumour unrelated to these diseases (e.g., adenomas).
NR: Not reported.
CPG & Syndromes vs. CPG & Diseases: \(p < 0.001\) (chi-squared test).

• Mortality: Recorded in only two cases. All other cases
being monitored/not reported.

Discussions

PGs in general and CPGs in particular are infrequent
tumours; in fact, the number of CPGs reported in Med
line/PubMed does not exceed 5,000 patients [5,47].
However, despite their low rate, the PGs that affect the
carotid body are the most common among those in the
head and neck.

The majority of CPGs are single tumours, Types I or II
of the Shamblin classification (and therefore resectable
without affecting the carotid axis), non-secretory and
benign; with expert treatment, this normal presenta
tion leads to excellent results. According to Al-Mefty
and Teixeira [48], the remaining CPGs are complex, with
one or more of the following characteristics: Very large,
attached to the carotid arteries (non-resectable or re-
1. Sporadic forms (the most frequent ones; there is a possibility of concealed paraganglioma)

2. Familial forms (relatively frequent) related to PGL syndromes:
- PGL1 (mechanism detected in SDHD gene). Frequency in multicentric PGs.
- PGL2 (genetic mechanism in SDHAF2 gene)
- PGL3 (mechanism detected in SDHC gene)
- PGL4 (mechanism detected in SDHB gene). Frequency in malignant forms.

3. Forms involving multiple systems (exceptionally associated with head and neck PGs):
   3.1. Associated with syndromes:
   - Von Hippel-Lindau (VHL) disease (mechanism detected in VHL gene)
   - Multiple endocrine neoplasia type II (mechanism detected in RET gene)
   - Neurofibromatosis type I (mechanism detected in NF1 gene)
   - Carney’s triad (unknown genetic mechanism, it may be familial)

   3.2. Not associated with syndromes (unknown genetic mechanisms):
   - Parathyroid adenoma
   - Astrocytoma
   - Thyroid carcinoma
   - Pituitary tumour

4. Unknown associations: Thymoma

PGs, paragangliomas.

*Modified of Baysal, 2001 [9] and Offergeld, et al. 2012 [12].

Table 4: Etiological/Molecular Classification of PGs of the Head and Neck.

| Description: Panas and Remy (1879). Eugen von Hippel (1895) and Arvid Lindau (1926). |
| Infrequent: 1/36,000 population. |
| Autosomal dominant hereditary character. |
| Mechanism detected: VHL gene mutation. |
| Type I (most common form; not PHEO); types IIA and IIB (including PHEO). |

| Lesion in HLD | Location |
|---------------|----------|
| Cysts         | Kidney, adrenal medulla, liver, lung, epididymis, omentum |
| Adenomas      | Adrenal cortex, liver, kidney, exocrine pancreas |
| Hemangioblastomas | Cerebellum, retina, kidney, pancreas |
| Neoplasms     | PHEO, islet cell tumour, meningioma, renal adenocarcinoma |
| Miscellanea   | Polycythaemia, syringomyelia, etc. |

Multiple Endocrine Neoplasia-type II (MEN-2) [29,49]

Two subtypes: MEN-2A (Sipple syndrome, 1961) and MEN-2B (1965).

Prevalence: 1/40,000.

Mechanism detected: RET gene mutation.

| MEN-2A | MEN-2B (marfanoid habitus) |
|--------|---------------------------|
| Medullary thyroid cancer (100%) | Medullary thyroid cancer (100%) |
| PHEO (40-50%) | PHEO (50%) |
| Parathyroid hyperplasia (20-30%) | Multiple mucosal neuromas (> 95%) |

Neurofibromatosis-type 1 (NF1) [39,50]

Synonymous: Von Recklinghausen disease.

Prevalence: 1/3,000-4,000.

Autosomal dominant hereditary character.

Mechanism detected: NF1 gene mutation.

Clinically, tumours (neurofibromas) form in nerve tissues at the following levels:

a) Deep layer of skin (subcutaneous tissue).
b) Nerves of the brain (cranial nerves) and spinal cord (nerves or spinal pairs).
head and neck PGs, which logically include CPGs, is conducted from an etiological/molecular perspective [9,12] with our interest focusing on those forms that involve multiple systems, and which are exceptionally associated with a PG (Table 4).

There are, in this sense, several syndromes (HLD, MEN-2B, NF1, Carney triad and CSS) related to PG/PHEO in general and PGC in particular, whose more salient aspects are shown in Table 5. Although these syndromes cannot be grouped, it may be said that they are all rare and the majority are hereditary, and a genetic mutation has been identified as their mechanism. It may also be affirmed that clinically speaking they are defined by the appearance of different tumours, which appear in different organs, at an early stage and throughout a patient’s lifetime (metachronous).

CPGs very rarely occur in these syndromes. HLD [30,32,35,41,45] and the Carney triad [27,28,43] are the least rare situations (five and nine cases, respectively). They reflect the complexity of these associations, which prompt the need to detect the different tumours, establish therapeutic priorities, and always make joint treatment decisions with other specialisms.

A second group of pathologies associated with CPGs contains parathyroid adenomas, astrocytomas, thyroid carcinomas and pituitary tumours. These situations also involve multiple systems, although they are not associated with syndromes such as the aforementioned ones. There is currently no evidence whatsoever regarding the possible existence of some form of genetic mechanism.

The most frequent situation is the association between a CPG and thyroid papillary cancer - the most common anatomopathological form of thyroid cancer. We have found nine, with highlights being the major personal pathological antecedents (multicentric CPGs, simultaneous PHEO, tumours in other locations, etc.) which logically further complicate these patients’ treatment [21,22,26,31,34,38,46]. Simultaneous surgery (thyroids and CPG) has been performed successfully on two occasions [22,24]; the resection of a CPG and a full thyroidectomy in the same successful surgical procedure has also been reported in situations involving a benign pathology of the thyroids [52]. Nevertheless, the decision to perform concomitant or sequential surgery on these patients should always be made on a case-by-case basis.

Finally, when the first mention was made in 2000 of the coexistence of a CPG and a thymoma, a situation that had not been described before, the authors wondered whether it was a random finding [40]; nevertheless, a possible common neuroectodermic origin may explain the coexistence of the CPG and multiple endocrine tumours. Despite the scant existing experience, both tumours can be successfully removed [24].

The low frequency and highly varied clinical manifestation of CPGs (biology and natural history) render these associations extremely unusual, and they clearly pose a diagnostic and therapeutic challenge for doctors. This is reflected in the experience of the Mayo Clinic (Rochester, Minnesota), which in one of the broadest PG series in the literature (236 patients, including 117 CPGs) records the following casuistry: Five PGs associated with HLD (2.1%), one PG associated with MEN-2B (0.4%), and four PGs forming part of the Carney triad (1.5%) [29].

In short, CPGs are infrequent tumours, of which approximately 25% are complex cases; they include situations that are even more exceptional (the syndromes and pathologies described in this article) with around 1% of the CPGs (3% of the complex CPGs).

The diagnostic and therapeutic strategy is crucial in these cases. The complexity of these associations, sometimes multiple and rare, means there is no diagnostic-therapeutic consensus in the literature, and decisions need to be taken on a case-by-case basis. Table 6 presents some general criteria accordingly: The mandatory need to find functional and supposedly malignant tumours,
4. Maxwell JG, Jones SW, Wilson E, Kotwall CA, Hall T, et al. (2004) Carotid body tumor excisions: Adverse outcomes of adding carotid endarterectomy. J Am Coll Surg 198: 36-41.

5. Robertson V, Poli F, Hobson B, Saratzis A, Ross Naylor A (2019) A systematic review and meta-analysis of the presentation and surgical management of patients with carotid body tumours. Eur J Vasc Endovasc Surg 57: 477-486.

6. Sajid MS, Hamilton G, Baker DM (2007) A multicenter review of carotid body tumour management. Eur J Vasc Endovasc Surg 34: 127-130.

7. Suarez C, Rodrigo JP, Mendenhall WM, Hamoir M, Silver CE, et al. (2014) Carotid body paragangliomas: A systematic study on management with surgery and radiotherapy. Eur Arch Otorhinolaryngol 271: 23-34.

8. Shamblin WR, ReMine WH, Sheps SG, Harrison EG Jr (1971) Carotid body tumor (chemodectoma). Clinicopathologic analysis of ninety cases. Am J Surg 122: 732-739.

9. Baysal BE (2001) Genetics of familial paragangliomas: Past, present, and future. Otolaryngol Clin North Am 34: 863-879.

10. Baysal BE (2002) Hereditary paraganglioma targets diverse paraganglia. J Med Genet 39: 617-622.

11. Koch CA, Vortmeyer AO, Zhuang Z, Brouwers FM, Pacak K (2002) New insights into the genetics of familial chromaffin cell tumors. Ann N Y Acad Sci 970: 11-28.

12. Offergeld C, Brase C, Yaremchuk S, Mader I, Rischke HC, et al. (2012) Head and neck paragangliomas: Clinical and molecular genetic classification. Clinics (Sao Paulo) 67: 19-28.

13. Hutton B, Catala-Lopez F, Moher D (2016) The PRISMA statement extension for systematic reviews incorporating network meta-analysis: PRISMA-NMA. Med Clin 147: 262-266.

14. Lozano FS, Muñoz A, de las Heras JA, González-Porras JR (2020) Simple and complex carotid paragangliomas. Three decades of experience and literature review. Head Neck 1-13.

15. Georgiadis GS, Lazarides MK, Tsalkidis A, Argyropoulou P, Giatromanolaki A (2008) Carotid body tumor in a 13-year-old child: Case report and review of the literature. J Vasc Surg 47: 874-880.

16. Ifeoluwa A, Lazar I, Szovordi E, Karosi T (2017) Management of carotid body tumor in pediatric patients: A case report and review of the literature. Int J Pediatr Otorhinolaryngol 93: 47-52.

**Table 6:** Carotid paragangliomas (CPG) related to syndromes and diseases.

| Relevant aspects |
|------------------|
| • Associations very infrequent, but situations do exist. Need for more knowledge. |
| • Associations of complex etiopathogenesis. Not fully clarified. |
| • Lack of specific diagnostic and therapeutic protocols. |
| • Search for tumours of various kinds, synchronous and metachronous. |
| • Functional situations (catecholamine secretion) and malignancy situations. |

| Diagnostic and therapeutic strategy (some aspects) |
|-----------------------------------------------|
| • Individualise therapeutic priorities: functional tumours? |
| • Interdisciplinary collaboration. |
| • Follow-up throughout life (metachronous tumours). |
| • Variable prognosis. There are situations of malignancy. |

prioritising the treatment of functional tumours, and the need for interdisciplinary approaches and monitoring because of the possibility of metachronous tumours.

**Acknowledgments**

To María Jesús Marcos Blázquez, from the Library of the Faculty of Medicine (University of Salamanca). Only her professionalism has allowed me to obtain hard-to-find articles in the shortest possible time.

**Declarations**

**Consent for publication**

All authors concur with the submission.

**Competing interests**

All authors declare no potential conflicts of interest and none of the data have been previously reported or are under consideration for publication elsewhere.

**Authors’ Contributions**

Conception and design: FSLS, AM, JAH, RGS, MBGC.

Data collection: FSLS, MBGC.

Analysis and interpretation of results: FSLS, AM, JAH, MBGC.

Writing up article (text, tables and figures): FSLS, MBGC.

Final approval of the article: FSLS, AM, JAH, RGS, MBGC.

**References**

1. Gonzalez-Orus Alvarez-Morujo RJ, Aristegui Ruiz MA, da Costa Belisario J, Martinez Guirado T, Scola Yurrita B (2015) Head and neck paragangliomas: Experience in 126 patients with 162 tumours. Acta Otorrinolaringol Esp 66: 332-341.

2. Sevilla Garcia MA, Llorente Pendas JL, Rodrigo Tapia JP, Garcia Rostan G, Suarez Fente V, et al. (2007) Head and neck paragangliomas: Revision of 89 cases in 73 patients. Acta Otorrinolaringol Esp: 58: 94-100.

3. Bikhaizi PH, Roeder E, Attaie A, Lalwani AK (1999) Familial paragangliomas: The emerging impact of molecular genetics on evaluation and management. Am J Otol 20: 639-643.

4. Maxwell JG, Jones SW, Wilson E, Kotwall CA, Hall T, et al. (2004) Carotid body tumor excisions: Adverse outcomes of adding carotid endarterectomy. J Am Coll Surg 198: 36-41.

5. Robertson V, Poli F, Hobson B, Saratzis A, Ross Naylor A (2019) A systematic review and meta-analysis of the presentation and surgical management of patients with carotid body tumours. Eur J Vasc Endovasc Surg 57: 477-486.

6. Sajid MS, Hamilton G, Baker DM (2007) A multicenter review of carotid body tumour management. Eur J Vasc Endovasc Surg 34: 127-130.

7. Suarez C, Rodrigo JP, Mendenhall WM, Hamoir M, Silver CE, et al. (2014) Carotid body paragangliomas: A systematic study on management with surgery and radiotherapy. Eur Arch Otorhinolaryngol 271: 23-34.

8. Shamblin WR, ReMine WH, Sheps SG, Harrison EG Jr (1971) Carotid body tumor (chemodectoma). Clinicopathologic analysis of ninety cases. Am J Surg 122: 732-739.

9. Baysal BE (2001) Genetics of familial paragangliomas: Past, present, and future. Otolaryngol Clin North Am 34: 863-879.

10. Baysal BE (2002) Hereditary paraganglioma targets diverse paraganglia. J Med Genet 39: 617-622.

11. Koch CA, Vortmeyer AO, Zhuang Z, Brouwers FM, Pacak K (2002) New insights into the genetics of familial chromaffin cell tumors. Ann N Y Acad Sci 970: 11-28.

12. Offergeld C, Brase C, Yaremchuk S, Mader I, Rischke HC, et al. (2012) Head and neck paragangliomas: Clinical and molecular genetic classification. Clinics (Sao Paulo) 67: 19-28.

13. Hutton B, Catala-Lopez F, Moher D (2016) The PRISMA statement extension for systematic reviews incorporating network meta-analysis: PRISMA-NMA. Med Clin 147: 262-266.

14. Lozano FS, Muñoz A, de las Heras JA, González-Porras JR (2020) Simple and complex carotid paragangliomas. Three decades of experience and literature review. Head Neck 1-13.

15. Georgiadis GS, Lazarides MK, Tsalkidis A, Argyropoulou P, Giatromanolaki A (2008) Carotid body tumor in a 13-year-old child: Case report and review of the literature. J Vasc Surg 47: 874-880.

16. Ifeoluwa A, Lazar I, Szovordi E, Karosi T (2017) Management of carotid body tumor in pediatric patients: A case report and review of the literature. Int J Pediatr Otorhinolaryngol 93: 47-52.
Kotsis T, Christoforou P, Nastos C (2019) Carotid paraganglioma in adolescence-clinical picture-surgical technique and review of the literature. Case Rep Vasc Med 2019.

Kuchakulla M, Shah AH, Armstrong V, Jernigan S, Bhatia S, (2018) Multimodal management of pediatric carotid body tumors: A systematic review and case illustrations. J Neurosurg Pediatr 23: 325-332.

Wing LA, Conaglen JV, Meyer-Rochow GY, Elston MS (2015) Paraganglioma in pregnancy: A case series and review of the literature. J Clin Endocrinol Metab 100: 3202-3209.

Lozano-Sanchez FS, Muñoz A, de las Heras JA, Taboada CR, García-Cenador MB (2020) Carotid paraganglioma synchronous with another ipsilateral carotid disease: A systematic literature review. World J Vasc Surg 3.

Albores-Saavedra J, Cuevas A, Luna-Olivares A, Brandt H, Rodríguez-Cuevas H (1968) Syndrome canceroma papilar-quimiodectoma y carcinoma-medular-feocromocitoma. Estudio comparative Prensa Med Mex 34: 334-342.

Albores-Saavedra J, Duran ME (1968) Association of thyroid carcinoma and chemodectoma. Am J Surg 116: 887-890.

Ali IM, Graham C, Sanallia B, Bell D (1994) Carotid body tumor associated with hyperparathyroidism. Ann Vasc Surg 8: 595-598.

Bano G, Sennik D, Kenchaiah M, Kyaw Y, Snape K, et al. (2015) A case of co-existing paraganglioma and thymoma. Springerplus 4: 632.

Berg B, Börkkuld A, Grimelius L, Ingemansson S, Larsson LI, et al. (1976) A new pattern of multiple endocrine adenomatosis: Chemodectoma, bronchial carcinoid, GH-producing pituitary adenoma, and hyperplasia of the parathyroid glands, and antral and duodenal gastrin cells. Acta Med Scand 200: 321-326.

Bugalho MJ, Silva AL, Domingues R (2015) Coexistence of paraganglioma/pheochromocytoma and papillary thyroid carcinoma: A four-case series analysis. Fam Cancer 14: 603-607.

Carney JA (1999) Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney Triad): Natural history, adrenocortical component, and possible familial occurrence. Mayo Clin Proc 74: 543-552.

Carney JA, Sheps SG, Go VL, Gordon H (1977) The triad of gastric leiomyosarcoma, functioning extra-adrenal paraganglioma and pulmonary chondroma. N Engl J Med 296: 1517-1518.

Erickson D, Kudva YC, Ebersold MJ, Thompson GB, Grant CS, et al. (2001) Benign paragangliomas: Clinical presentation and treatment outcomes in 236 patients. J Clin Endocrinol Metab 86: 5210-5216.

Gross DJ, Avishai N, Meiner V, Filon D, Zbar B, et al. (1996) Familial pheochromocytoma associated with a novel mutation in the von Hippel-Lindau gene. J Clin Endocrinol Metab 81: 147-149.

Huguet I, Walker L, Karavitaki N, Byrne J, Grossman AB (2013) Dandy-Walker malformation, papillary thyroid carcinoma, and SDHD-associated paraganglioma syndrome. J Clin Endocrinol Metab 98: 4595-4596.

Hull MT, Roth LM, Glover JL, Walker PD (1982) Metastatic carotid body paraganglioma in von Hippel-Lindau disease. An electron microscopic study. Arch Pathol Lab Med 106: 235-239.

Larraza-Hernandez O, Albores-Saavedra J, Benavides G, Krause LG, Perez-Merizaldi C, et al. (1982) Multiple endocrine neoplasia: Pituitary adenoma, multicentric papillary thyroid carcinoma, bilateral carotid body paraganglioma, parathyroid hyperplasia, gastric leiomyoma, and systemic amyloidosis. Am J Clin Pathol 78: 527-532.

Lin B, Yang HY, Yang HJ, Shen SY (2019) Concomitant paraganglioma and thyroid carcinoma: A case report. World J Clin Cases 7: 656-662.

Majchrzak K, Cybulski C, Bobek-Billewicz B, Majchrzak H, Lubinski J (2011) A case of carotid body paraganglioma and haemangioblastoma of the spinal cord in a patient with the N131K missense mutation in the VHL gene. Neurol Sci 32: 491-496.

Nicholas RS, Quddus A, Topham C, Baker D (2015) Resection of a large carotid paraganglioma in Carney-Stratakis syndrome: A multidisciplinary feat. BMJ Case Rep Rep 2015.

Ophir D (1991) Familial multicentric paragangliomas in a child. J Laryngol Otol 105: 376-380.

Papathomas TG, Gaal J, Corssmit EP, Oudijk L, Korper-sheok E, et al. (2014) Non-pheochromocytoma (PCC)/paraganglioma (PGL) tumors in patients with succinate dehydrogenase-related PCC-PGL syndromes: A clinicopathological and molecular analysis. Eur J Endocrinol 170: 1-12.

Petr EJ, Else T (2018) Pheochromocytoma and Paraganglioma in Neurofibromatosis type 1: Frequent surgeries and cardiovascular crises indicate the need for screening. Clin Diabetes Endocrinol 4: 15.

Reflor M, Mees K (2000) Coexistence of bilateral paraganglioma of the A. carotis, thymoma and thyroid adenoma: A chance finding? Laryngo-rhino-otologie 79: 337-340.

Schimke RN, Collins DL, Rothberg PG (1998) Functioning carotid paraganglioma in the von Hippel-Lindau syndrome. Am J Med Genet 80: 533-534.

Steely WM, Davies RS, Brigham RA (1987) Carotid body tumor and hyperparathyroidism. A case report and review of the literature. Am Surg 53: 337-338.

Wintemark P, Boubaker A, Gebhard S, Meuli R, Bettschart V, et al. (2001) Adrenal mass in carney triad. International Journal on Disability and Human Development 2: 229-240.

Xekouki P, Pacak K, Almeida M, Wassif CA, Rustin P, Nes-terova M, et al. (2012) Succinate dehydrogenase (SDH) D subunit (SDHD) inactivation in a growth-hormone-producing pituitary tumor: A new association for SDH? The J Clin Endocrinol Metab 97: E357-E366.

Zanelli M, van der Walt JD (1996) Carotid body paraganglioma in von Hippel-Lindau disease: A rare association. Histopathology 29: 178-181.

Zibuk KM, Patocs A, Shealy A, Sylvester H, Miesfeldt S, et al. (2007) Germline mutations in PTEN and SDHC in a woman with epithelial thyroid cancer and carotid paraganglioma. Nat Clin Pract Oncol 4: 608-612.

Lozano Sanchez FS, Munoz Herrera A (2009) Surgical treatment of carotid paragangliomas. Acta Otorrinolaringol Esp 1: 80-96.

Al-Mefty O, Teixeira A (2002) Complex tumors of the glo-ssou-maxillary sinus. Journal on Disability and Human Development 2: 229-240.

Gruber LM, Erickson D, Babovic-Vuksanovic D, Thompson GB, Young Jr WF, et al. (2017) Pheochromocytoma and paraganglioma in patients with neurofibromatosis type 1. Clin Endocrinol (Oxf) 86: 141-149.
50. Carney JA (2009) Carney triad: A syndrome featuring paraganglionic, adrenocortical, and possibly other endocrine tumors. J Clin Endocrinol Metab 94: 3656-3662.

51. Stratakis C, Carney J (2009) The triad of paragangliomas, gastric stromal tumours and pulmonary chondromas (Carney triad), and the dyad of paragangliomas and gastric stromal sarcomas (Carney-Stratakis syndrome): Molecular genetics and clinical implications. J Intern Med 266: 43-52.

52. Garcia Alva R, Bobadilla Rosado LO, Arzola LH, Escobar Preciado M, Anaya Ayala JE, et al. (2018) A case report of a concomitant total thyroidectomy and carotid body tumor resection in a 43 year old female. Int J Surg Case Rep 53: 17-20.